Advertisement

Topics

Positive phase III results for Sandoz etanercept biosimilar

05:04 EDT 23 Sep 2016 | Generics and Biosimilars Initiative

Results of a study of Sandoz’s etanercept biosimilar (GP2015) compared to Amgen/Pfizer’s arthritis blockbuster Enbrel (etanercept) have shown ‘equivalent efficacy’, according to the company.

Original Article: Positive phase III results for Sandoz etanercept biosimilar

NEXT ARTICLE

More From BioPortfolio on "Positive phase III results for Sandoz etanercept biosimilar"

Quick Search
Advertisement
 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...